alexa Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.
Immunology

Immunology

Journal of Vaccines & Vaccination

Author(s): Quan FS, Vunnava A, Compans RW, Kang SM

Abstract Share this page

Abstract BACKGROUND: The 2009 influenza pandemic and shortages in vaccine supplies worldwide underscore the need for new approaches to develop more effective vaccines. METHODOLOGY/PRINCIPAL FINDINGS: We generated influenza virus-like particles (VLPs) containing proteins derived from the A/California/04/2009 virus, and tested their efficacy as a vaccine in mice. A single intramuscular vaccination with VLPs provided complete protection against lethal challenge with the A/California/04/2009 virus and partial protection against A/PR/8/1934 virus, an antigenically distant human isolate. VLP vaccination induced predominant IgG2a antibody responses, high hemagglutination inhibition (HAI) titers, and recall IgG and IgA antibody responses. HAI titers after VLP vaccination were equivalent to those observed after live virus infection. VLP immune sera also showed HAI responses against diverse geographic pandemic isolates. Notably, a low dose of VLPs could provide protection against lethal infection. CONCLUSION/SIGNIFICANCE: This study demonstrates that VLP vaccination provides highly effective protection against the 2009 pandemic influenza virus. The results indicate that VLPs can be developed into an effective vaccine, which can be rapidly produced and avoid the need to isolate high growth reassortants for egg-based production.
This article was published in PLoS One and referenced in Journal of Vaccines & Vaccination

Relevant Expert PPTs

Relevant Speaker PPTs

  • Ivana Stojanovic
    New protocol for the generation of insulin-specific T regulatory cells
    PPT Version | PDF Version
  • Jessy S Deshane
    Longitudinal changes in airway microbiome signatures and immunoregulatory cell dynamics following Bronchial Thermoplasty
    PPT Version | PDF Version
  • Luis Gosalbez
    Key regulatory issues in the development of pharmabiotics in Europe
    PPT Version | PDF Version
  • Brian Littlechild
    The management of violence and aggression against staff in mental health work: responding effectively through a co-production approach to issues for service users, carers, staff and agencies
    PPT Version | PDF Version
  • Ganesh Raj Pant
    A serological study in response to people at occupational risk of rabies virus exposure in Nepal
    PPT Version | PDF Version
  • Daniela Pencheva
    BUL BIO-NCIPD
    PPT Version | PDF Version
  • Wendy peters
    A non-replicating Ad5 vaccine for treatment of HSV-2
    PPT Version | PDF Version
  • Randa Hamadeh
    Polio returns to Middle East, situation analysis, strategies and way forward
    PPT Version | PDF Version
  • Luiza Guilherme
    Streptococcus pyogenes candidate vaccine
    PPT Version | PDF Version
  • Xiao-Song He
    Distinct priming effect of live attenuated versus inactivated influenza vaccines in repeated influenza vaccination
    PPT Version | PDF Version
  • Stephanie Ramos
    Enhanced Delivery of Dna-Based Vaccines and Immunotherapeutics through Next-Generation Electroporation Devices
    PPT Version | PDF Version
  • Manoj Kumar Chhikara
    How promising is the development of a semi-synthetic meningococcal conjugate vaccine ?
    PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Charani ranasinghe
    Unique IL-4R antagonist and IL-13Ra2 adjuvanted pox viral vector-based HIV vaccines
    PPT Version | PDF Version
  • Kazuo Yano
    Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords